| DC66725 |
Myristyl-γ-picolinium Chloride
Featured
|
|
|
| DC66726 |
(-)-Ethyl L-Lactate
Featured
|
|
|
| DC66727 |
Gentisic Acid Ethanolamide
Featured
|
Gentisic acid ethanolamide is a complexing agent in pharmaceutical parenterals. It is used as a solubilizer in some pharmaceutical preparations and as an antiseptic agent. |
|
| DC66728 |
Acetyltriethyl citrate
Featured
|
Acetyltriethyl citrate is a biochemical. |
|
| DC66729 |
Polyquaternium-1
Featured
|
Polyquaternium-1 (Polidronium chloride) is a polycationic ophthalmic preservative. Polyquaternium-1 can inhibit growth of microbial contaminants in multi-dose bottles of topical medications. |
|
| DC66732 |
α-Lactose hydrate
Featured
|
α-Lactose (hydrate) (α-D-Lactose (hydrate)) is the principal carbohydrate in the milk of most mammals. α-Lactose (hydrate) consists of glucose and galactose and exists in the form of two anomers, α and β. α-Lactose (hydrate) has many uses in the food and pharmaceutical industries, such as a free-flowing or agglomerating agent, a diluent for pigments, flavors, or enzymes. |
|
| DC60647 |
AZ'3137
Featured
|
AZ'3137 is an orally bioavailable androgen receptor (AR) degrader that recruit the Cereblon (CRBN) E3 ligase with DC50 of 22 nM (LNCaP) and 92 nM (LNCaP L720H), respectively. |
|
| DC60648 |
CB31
Featured
|
CB31 is a highly potent and orally bioavailable PD-L1 inhibitor with IC50 of 0.2 nM (PD-1/PD-L1 alphs) and EC50 of 15 nM (NFAT), with high passive permeability, good metabolic stability and favorable oral PK. CB31 targets both the surface and intracellular PD-L1, reducing tumor size and killing cells in a 3D spheroid model. |
|
| DC60649 |
Compound 13 (MET inhibitor)
Featured
|
Compound 13 (MET inhibitor) is a selective, potent, and mutant-active MET inhibitor with a MET D1228N cell line IC50 of 23 nM and shows good efficacy in the MET-D1228N Type I resistance mutation model. |
.jpg)
|
| DC60650 |
A-910
Featured
|
A-910 is a orally bioavailable, highly potent and selective dual MerTK/Axl inhibitor with IC50 of 0.3 nM/0.8 nM. A-910 exhibits favorable oral bioavailability, exceptional kinome selectivity, and significantly improved in MerTK Ba/F3 xenograft tumor model. |
|
| DC60651 |
R1-ICR-5
Featured
|
R1-ICR-5 is a highly selective and efficacious PROTAC degrader of both human and murine RIPK1. |
|
| DC60652 |
Compound 12f (LPA1 antagonist)
Featured
|
Compound 12f (LPA1 antagonist) is a potent and highly selective LPA1 antagonist with IC50 of 16.0 nM (cAMP assay) and 18.4 nM (calcium mobilization assay), respectively. |
.png)
|
| DC66734 |
Semaglutide acetate
Featured
|
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment. |
|
| A132 |
U.Washington patent anti-GAD65 Biosimilar（Anti-GAD65 Reference Antibody）
Featured
|
|
|
| A133 |
Crotedumab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. |
.png)
|
| A134 |
Volagidemab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D). |
.png)
|
| A135 |
Naxitamab Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. |
.png)
|
| A136 |
Lorukafusp alfa Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. |
.png)
|
| A137 |
Ecromeximab Biosimilar（Anti-GD3 Reference Antibody）
Featured
|
Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells. |
.png)
|
| A138 |
Ponsegromab Biosimilar（Anti-GDF15 / MIC1 Reference Antibody）
Featured
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. |
.png)
|
| A139 |
Apitegromab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. |
.png)
|
| A140 |
Trevogrumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake. |
.png)
|
| A141 |
Landogrozumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease. |
.png)
|
| DC66745 |
Cbl-b-IN-10
Featured
|
Cbl-b-IN-10 (Compound 463) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 6.0 nM and 3.5 nM, respectively. |
|
| A142 |
Lintuzumab Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice. |
.png)
|
| A143 |
NGM120 Biosimilar（Anti-GFRAL Reference Antibody）
Featured
|
|
|
| A144 |
Amgen patent anti-GIPR Biosimilar（Anti-GIPR Reference Antibody）
Featured
|
|
|
| A145 |
Centocor patent anti-GLP-1R Biosimilar(Anti-GLP1R Reference Antibody)
Featured
|
|
|
| A146 |
Cureab patent anti-GP73 Biosimilar(Anti-GOLM1 Reference Antibody)
Featured
|
|
|
| A147 |
Glenzocimab Biosimilar(Anti-GP6 / Glycoprotein-6 Reference Antibody)
Featured
|
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. |
.png)
|
